| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Active Research
Forum: Mapping Cancer Markers Forum
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 533
|
|
| Author |
|
|
Seoulpowergrid
Veteran Cruncher Joined: Apr 12, 2013 Post Count: 823 Status: Offline Project Badges: 
|
Novel Technology for Anticancer Drug Delivery On Demand
----------------------------------------- Light-responsive vesicles carry and release...cific time and position - "“We thought to take advantage of this newly discovered property and use these vesicles as vehicles to carry anticancer drugs. Then, by controlling when and where the vesicles are broken, the drugs could be released on demand.”" ... "Rather than using UV single-photon laser to promote the glutathione-allyloxy tail reaction, IBS researchers employed a near infrared two-photon laser, which has the ability to penetrate deeper into tissues with increased accuracy. In simple terms, the two-photon laser (wavelength 720 nanometers) is a better tool to use than a single-photon laser (365 nanometers) as it can reach deeper inside flesh with less scattering. As the irradiated area is smaller, the drug delivery is confined to the targeted area, resulting in less damage to healthy tissue surrounding the tumor."  |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 669 Status: Offline Project Badges: 
|
A Cancer 'Vaccine' Cured 97% of Tumors in Mice. What's That Mean for People?
A promising new cancer "vaccine" that cured up to 97% of tumors in mice will soon be tested in humans for the first time-but experts say that we're still a long way from this type of drug being prescribed to cancer patients. Researchers from Stanford University will test the therapy in about 35 people with lymphoma by the end of the year. Dr. Alice Police, the regional director of breast surgery at Northwell Health Cancer Institute in Westchester, New York, who was not involved in the study, said that the news of a human trial to test this treatment is "exciting." However, she cautioned that results in animal studies don't always translate to people. https://www.livescience.com/62161-cancer-vacc...;utm_campaign=20180329lsh  |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 669 Status: Offline Project Badges:
|
NIH completes in-depth genomic analysis of 33 cancer types
The Cancer Genome Atlas (TCGA), supported by NIH's NHGRI and NCI, concludes with an in-depth genomic analysis of 33 cancer types called the PanCancer Atlas. Findings are being published as a collection of 27 papers across multiple Cell journals. https://www.cancer.gov/news-events/press-rele...ancer-Atlas?cid=eb-govdel |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Chemotherapy-free treatment for blood cancers
A breakthrough in chemotherapy-free cancer treatment by Melbourne researchers has doubled the survival rate of patients with some forms of blood cancer. Scientists at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital have found 85 per cent of patients with chronic leukaemia and lymphoma were cancer-free after two years while on a novel combination of cancer-melting drugs. The breakthrough means people suffering from hard-to-treat forms of blood cancer could soon be able to take tablets, rather than rely on conventional treatments like chemotherapy and radiation. Two clinical trials of Venetoclax, which was first developed based on research conducted in Melbourne in the 1980s, have found the drug, combined with cancer drugs Rituximab or Ibrutinib, doubled the survival chances of people with chronic lymphocytic leukaemia (CCL) and mantle cell lymphoma (MCL). [. . .] "Most remarkably, the rate of achieving no detectable leukaemia by our most sensitive tests in the blood of these patients was 85 per cent with the novel treatment and only 23 per cent with our previous chemotherapy." More at http://www.abc.net.au/news/2018-04-05/cancer-...ymphoma-leukaemia/9622570 |
||
|
|
[VENETO] boboviz
Senior Cruncher Joined: Aug 17, 2008 Post Count: 184 Status: Offline Project Badges: 
|
NIH completes in-depth genomic analysis of 33 cancer types The Cancer Genome Atlas (TCGA), supported by NIH's NHGRI and NCI, concludes with an in-depth genomic analysis of 33 cancer types called the PanCancer Atlas. Findings are being published as a collection of 27 papers across multiple Cell journals. https://www.cancer.gov/news-events/press-rele...ancer-Atlas?cid=eb-govdel It's an impressive research! |
||
|
|
pcwr
Ace Cruncher England Joined: Sep 17, 2005 Post Count: 10903 Status: Offline Project Badges: 
|
----------------------------------------  |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 669 Status: Offline Project Badges:
|
In-depth genomic analysis of 33 cancer types - Three-day symposium Washington, D.C. September 27-29, 2018
There will be a three-day Symposium, TCGA Legacy Multi-Omic Studies in Cancer, in Washington, D.C., September 27-29, 2018 that will discuss the future of large-scale cancer studies, with a session focusing on the PanCancer Atlas. The meeting will feature the latest advances on the genomic architecture of cancer and showcase recent progress toward therapeutic targeting. https://www.sciencedaily.com/releases/2018/04/180405183629.htm |
||
|
|
QuantumEthos
Senior Cruncher Joined: Jul 2, 2011 Post Count: 336 Status: Offline Project Badges: 
|
|
||
|
|
pcwr
Ace Cruncher England Joined: Sep 17, 2005 Post Count: 10903 Status: Offline Project Badges:
|
---------------------------------------- |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
A new cancer drug known as BLU-667 has moved through phase I human trials, and the results are promising. Taken orally, the drug targets what are known as RET-driven cancers, including types of thyroid and lung cancers, which are normally hard to treat. Among others, RET [RET is a type of receptor tyrosine kinase] plays a role in around 50 percent of medullary thyroid cancers, 20 percent of papillary thyroid cancers, and up to two percent of non-small cell lung cancers.
----------------------------------------[. . . ] BLU-667 works by inhibiting the activity of RET, and it was chosen for further study after it was found to be 100 times more selective for RET, meaning it shouldn't affect the functions of other kinases. More at https://newatlas.com/clinical-trial-results-ret-cancer-drug/54216/ [Edit 1 times, last edit by l_mckeon at Apr 17, 2018 1:20:18 AM] |
||
|
|
|